All In MedTech

FDA Clearance Tracker · P040029-S017

Orthokeratology (tisilfocon A) Contact Lenses for Overnight Wear

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Mar 30, 2021 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Mar 30, 2021

Approved

Time to decision

172 days

Received Oct 9, 2020. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track No User Fee

Device class

Class III

The decision

FDA number
P040029-S017
Device name
Orthokeratology (tisilfocon A) Contact Lenses for Overnight Wear
Applicant location
Sterling, VA
Received
Oct 9, 2020
Decided
Mar 30, 2021
Decision
Approved
Supplement type
Normal 180 Day Track No User Fee
Reason for supplement
Labeling Change - Indications/instructions/shelf life/tradename
Original approval
P040029

Device type

Device class
Class III
Regulation
21 CFR 886.5916
Specialty
Ophthalmology

Every decision under product code NUU

FDA's approval statement

As written in FDA's record.

Approval for model name additions to the Euclid Systems Orthokeratology (tisilfocon A) Contact Lenses for Overnight Wear

Source documents

Other decisions for Euclid Vision Corporation

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

No other decisions since 2015 under this exact applicant name.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.